局部晚期可切除直肠癌术前短程放疗联合化疗与长程放化疗的成本效果分析
基于NCT00833131试验的Markov模型,从中国支付方角度比较术前短程放疗(SCRT,5×5 Gy)联合FOLFOX4与长程放化疗(LCCRT,50.4 Gy/28次)治疗cT4或晚期cT3直肠癌的成本效果。SCRT联合化疗总成本更高($78,937 vs $38,140)但获得更多质量调整生命月(29.92 vs 22.99),增量成本效果比(ICER)为$5884.56/QALM;在无病生存(DFS)状态ICER为$339.50/QALM,低于支付意愿阈值$2370.47/QALM。结论:SCRT联合化疗在DFS状态以及当进展状态成本低于$1920时更具成本效果。
要点
- SCRT联合化疗较LCCRT增加6.93 QALM,ICER为$5884.56/QALM。
- DFS状态ICER为$339.50/QALM,低于WTP阈值$2370.47/QALM。
- 进展状态成本低于$1920时,SCRT联合化疗在全状态具成本效果。
核心结论
- 与LCCRT相比,SCRT联合化疗在DFS状态以及进展状态成本低于$1920时,是局部晚期可切除直肠癌更具成本效果的策略。
研究设计与样本
- 采用Markov决策分析模型,模拟DFS、进展和死亡三种健康状态,比较SCRT联合化疗与LCCRT。
- 转移概率基于NCT00833131试验,成本从中国支付方角度计算,WTP阈值为$2370.47/QALM。
主要发现
- SCRT联合化疗与LCCRT总成本分别为$78,937和$38,140,效果分别为29.92和22.99 QALMs。
- SCRT联合化疗较LCCRT增加成本$40,797.34和QALM 6.93,ICER为$5884.56/QALM。
- DFS状态成本分别为$11,490.03和$10,794.06,效果分别为21.70和19.65 QALMs,ICER为$339.50/QALM。
- DFS状态效用是影响SCRT联合化疗成本效果的最主要因素。
- 当进展状态成本低于$1920时,SCRT联合化疗对比LCCRT的ICER低于WTP阈值。
关键数值与推荐
- WTP阈值为$2370.47/QALM(3倍GDP)。
- DFS状态ICER为$339.50/QALM,低于WTP阈值。
- 进展状态成本阈值$1920,低于此值时SCRT联合化疗在全状态具成本效果。
临床怎么用
- 在DFS状态或进展状态成本较低(<$1920)时,可优先考虑SCRT联合化疗作为更具成本效果的策略。
- 决策时需关注DFS状态效用值及进展状态成本对成本效果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the cost-effectiveness of preoperative short-course radiotherapy (SCRT, 5 × 5 Gy) plus FOLFOX4 versus long-course oxaliplatin and bolus of fluorouracil based preoperative long-course chemoradiotherapy (LCCRT, 50.4 Gy in 28 fractions) in the management of cT4 or advanced cT3 rectal cancer (RC), both of which have been reported to achieve similar clinical effect in the NCT00833131 trial. MATERIALS AND METHODS: A Markov decision-analytic model compared SCRT plus chemotherapy and LCCRT, by simulating three health states (disease-free survival (DFS), progressive disease (PD) and death). The primary outcomes were quality-adjusted life months (QALMs), costs, and incremental cost-effectiveness ratios (ICERs). Transition probabilities were based on the NCT00833131 trial. The costs were calculated from a Chinese payers' perspective. Strategies were evaluated with a willingness-to-pay (WTP) threshold of $2370.47 (3 × GDP) per QALM gained. Sensitivity analysis was performed to model uncertainty in these parameters. RESULTS: The overall costs for SCRT plus chemotherapy and LCCRT were $78,937 and $38,140 with effectiveness of 29.92 QALMs and 22.99 QALMs, respectively. SCRT plus chemotherapy increased costs and QALM by $40,797.34 and 6.93 compared to LCCRT, resulting in an ICER of $5884.56/QALM gained. In the DFS state, the whole cost for SCRT plus chemotherapy and LCCRT were $11,490.03 and $10,794.06 with an effectiveness of 21.70 QALMs and 19.65 QALMs, respectively. SCRT plus chemotherapy increased cost and QALM by $695.97 and 2.05 compared to LCCRT, resulting in a ICER of $339.50/QALM gained, which below the WTP. The utility associated with the DFS state was the most influential factor on the cost-effectiveness of SCRT plus chemotherapy. When the cost of PD state below $1920, the ICER of SCRT compared with LCCRT below the WTP. CONCLUSION: Compared with LCCRT, SCRT plus chemotherapy is a more cost-effective strategy for locally advanced resectable RC in the DFS state as well as in the all states when the cost of PD state below $1920.
引用
- Wang S, Wen F, Zhang P, et al. Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer. Radiat Oncol. 2019. PMID: 31234886. doi:10.1186/s13014-019-1319-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。